左卡尼汀对终末期肾病血液透析患者心脏结构和功能的影响

摘要

Objective To analyze the effects of L-carnitine on cardiac structure and function in hemodialysis patients with end-stage renal disease. Methods 65 patients with nephrotic dialysis who were treated from March 2015 and October 2016 were collected and divided into observation group (33 cases) and control group (32 cases). The observation group with L-carnitine treatment, the control group was treated with conventional therapy, and the therapeutic effects of the two groups were compared.Results The level of LVEF and E/A in the observation group were higher than those in the control group, LVMI and LVEDD were lower than those in the control group (P < 0.05). The incidence of adverse events in the observation group was 6.25%, which was lower than that in the control group (21.88%) (P < 0.05). Conclusion Patients with end-stage hemodialysis nephropathy to be treated with levocarnitine can effectively improve the symptoms of left ventricular hypertrophy and improve cardiac function.%目的：分析左卡尼汀对终末期肾病血液透析患者心脏结构和功能的影响。方法选取2015年3月-2016年10月治疗的65例肾病透析患者作为研究对象，将其随机分为观察组（33例）、对照组（32例），观察组采用左卡尼汀治疗，对照组采用常规治疗，比较两组治疗效果。结果观察组LVEF、E/A水平高于对照组，LVMI、LVEDD水平低于对照组（P＜0.05）；观察组不良情况发生率为6.25%，低于对照组21.88%（P＜0.05）。结论终末期血液透析肾病患者予以左卡尼汀治疗可有效改善患者左室肥厚症状并且改善心功能。